Table 2.
Clinical characteristics of the subjects under telbivudine therapy for longitudinal study.
| Group | CR | NCR | p-Value | |
|---|---|---|---|---|
| N | 18 | 23 | ||
| Gender (M/F) | 15/3 | 21/2 | 0.638a | |
| Age (years) | 27.5 (18–42) | 28 (18–40) | 0.989b | |
| 0 weeks | HBV-DNA (log10 copies/ml) | 8.52 (5.78–9.43) | 8.63 (6.56–9.7) | 0.121b |
| ALT (U/l) | 118 (60–830) | 130 (55–324) | 0.655b | |
| HBsAg (log10 IU/ml) | 4.16 (2.53–4.66) | 4.45 (3.24–5.07) | 0.088b | |
| HBeAg (log10 PEIU/ml) | 2.38 (0.36–3.79) | 3.11 (1.33–3.93) | 0.189b | |
| 12 weeks | HBV-DNA (log10 copies/ml) | 3.13 (2.08–4.97) | 3.99 (2.34–5.93) | 0.009b |
| ALT (U/l) | 29.5 (15–160) | 40 (16–211) | 0.098b | |
| HBsAg (log10 IU/ml) | ND | ND | ||
| HBeAg (P/N) | 12/6 | 23/0 | 0.004a | |
| 24 weeks | HBV-DNA (log10 copies/ml) | 2.38 (1.84–4.09) | 3.01 (1.84–5.27) | 0.025b |
| ALT (U/l) | 23.5 (14–65) | 25 (14–63) | 0.493b | |
| HBsAg (log10 IU/ml) | 3.24 (2.07–4.21) | 3.74 (3.09–4.69) | 0.009b | |
| HBeAg (P/N) | 11/7 | 23/0 | 0.001a | |
| 52 weeks | HBV-DNA (log10 copies/ml) | 1.84 (1.84–2.09) | 1.84 (1.84–4.840) | 0.006b |
| ALT (U/l) | 19.5 (13–56) | 19 (12–52) | 0.544b | |
| HBsAg (log10 IU/ml) | 3.34 (1.88–4.11) | 3.86 (2.90–4.76) | 0.006b | |
| HbeAg (P/N) | 0/18 | 23/0 | 0.000a | |
Values are n or median (range).
aChi-squared test.
bMann–Whitney U-test.
M/F, male or female; ND, not determined; P/N, positive or negative; CR, complete response, patients with HBeAg seroconversion at week 52; NCR, non-complete response, patients without HBeAg seroconversion at week 52; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.